Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance
Filings
18 filings of WOCKPHARMA since February 2025.
board outcome 8, presentation 4, results 2, transcript 2, credit rating 2
| Filed | Type | Subject | |
|---|---|---|---|
| 02 Nov 2026 | board outcome Results | Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations ); and in continuation to our letter bearing reference no: WOCK/SEC/SE/2026-27/042AI summaryWockhardt Limited filed the outcome of its board meeting held on 2nd November, 2026, approving the unaudited standalone and consolidated financial results for the quarter and half year ended 30th September, 2026. Standalone revenue from operations was Rs 580 crore for the quarter ended 30/09/2026 (Rs 561 crore in the previous quarter) and Rs 1,141 crore for the six months ended 30/09/2026 (Rs 793 crore a year earlier). Standalone net profit after tax was Rs 100 crore for the quarter ended 30/09/2026 and Rs 207 crore for the six months ended 30/09/2026 (Rs 123 crore a year earlier). Basic EPS was Rs 6.15 for the quarter ended 30/09/2026 and Rs 12.77 for the six months ended 30/09/2026 (not annualised). The Limited Review Report was issued by MSKC & Associates LLP, Statutory Auditors, with no matters reported. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 10 Aug 2026 | board outcome Results | Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations ); and in continuation to our letter bearing reference no: WOCK/SEC/SE/2026-27/027AI summaryWockhardt Limited filed the outcome of its board meeting held on 10 August 2026, approving the unaudited standalone and consolidated financial results for the quarter ended 30 June 2026, with a limited review report from statutory auditors MSKC & Associates LLP. Standalone revenue from operations for the quarter ended 30 June 2026 was Rs 561 crore, against Rs 413 crore in the corresponding quarter of the previous year. Standalone net profit after tax for the quarter was Rs 107 crore, against Rs 69 crore in the corresponding quarter of the previous year. Standalone basic earnings per share for the quarter was Rs 6.62 (not annualised). The board meeting commenced at 1:10 p.m. and concluded at 3:05 p.m. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 11 Jun 2026 | transcript Guidance, Legal, Results | Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations andDisclosure Requirements) Regulations, 2015, as amended and in continuation to our letter bearing reference no. Ref. No.: WOCK/SEC/SE/2025-26/015AI summaryWockhardt Limited filed the transcript of its investor conference/call held on 4 June 2026, with a link to the transcript on its website. Management said Zaynich has received US FDA approval (first Indian-discovered new drug approved by the US FDA, per the filing) and will be launched in the US and India in the current year, with Europe and emerging markets in later years. Management reported FY results of revenue INR3,373 crores, EBITDA of about INR630 crores (growth of about 51%), profit before tax of INR238 crores, cash equivalents of INR662 crores and net debt-to-equity of 0.1. Management said EBITDA margin rose from about 5.4% three years ago to 18.6%, and that the specialty business (biosimilars and novel antibiotics) contributes 23% of business. Management said the diabetes biosimilar business grew about 35%, emerging markets grew 35% to 28% of turnover, and the UK business grew 13% and makes up 39% of turnover. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 Jun 2026 | presentation Results | Wockhardt Limited has informed the Exchange about Investor PresentationAI summaryWockhardt Limited filed its investor presentation for an investor conference to be held on 4 June 2026, also uploaded to the company website. The presentation covers an overview of the company as a global innovation-led healthcare company across novel antibiotics, biotechnology (diabetes biosimilars) and pharmaceuticals, with 11 manufacturing facilities and 2 R&D centres (India and UK). Key FY26 figures shown: income INR 3,373 Cr, EBITDA INR 630 Cr (51% year-on-year EBITDA growth), PBT INR 238 Cr. As at 31 March 2026, cash and cash equivalents stood at INR 662 Cr and the net debt to equity ratio was 0.10 (excluding promoter debt). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 21 May 2026 | credit rating Rating | Wockhardt Limited has informed the Exchange about Credit RatingAI summaryICRA Limited has upgraded Wockhardt Limited's credit ratings, as disclosed in the filing dated 21 May 2026. Long-term Fund Based Term Loan A- (Stable), previously BBB (Positive). Long-term/short-term Fund Based and Non Fund Based facilities and Unallocated Limits rated A- (Stable)/A2+, previously BBB (Positive)/A3+. ICRA cited improved financial performance, healthy formulation market position in India and Europe, improving emerging market position, adequate liquidity, comfortable capital structure, and strengthened financial metrics with scale expansion of value-accretive products and new chemical entities. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 May 2026 | board outcome Capex, Dividend / buy-back, Results | Pursuant to Regulation 30 and 33 of Listing Regulations read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations ); and in continuation to ourAI summaryBoard of Wockhardt Limited met on 4 May 2026 (from 11:00 a.m. to 3:10 p.m.) and approved the audited standalone and consolidated financial results for the quarter and financial year ended 31 March 2026, with the Statutory Auditor's report from M/s MSKC & Associates LLP. The Board also approved an enabling proposal to raise funds through issue of equity shares, convertible or non-convertible securities, via public/private offerings, QIP, preferential allotment or any other permitted method, subject to shareholder consent at the ensuing AGM. The auditor's report on the standalone results gives an unmodified opinion, and a declaration on the unmodified opinion is enclosed. The auditor's report notes that Q4 figures are the balancing figure between audited full-year and published unaudited nine-month figures. The pages provided do not state the revenue, profit or dividend figures. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 May 2026 | board outcome Capex, Dividend / buy-back, Results | Pursuant to Regulation 30 and 33 of Listing Regulations read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations ); and in continuation to ourAI summaryBoard of Wockhardt Limited met on 4 May 2026 (11:00 a.m. to 3:10 p.m.) and approved the audited standalone and consolidated financial results for the quarter and financial year ended 31 March 2026, along with the statutory auditor's report from MSKC & Associates LLP and a declaration on unmodified audit opinion. The Board also approved an enabling proposal to raise funds through issue of equity shares, convertible securities, non-convertible securities or combinations, via public/private offerings, QIP and/or preferential allotment, subject to shareholder consent at the ensuing AGM. The auditor's report states the standalone results give a true and fair view and are presented in line with Regulation 33 of the Listing Regulations. The filing does not state the revenue, profit or dividend figures; those are in the enclosed annexures, which were not included in the pages provided. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 10 Feb 2026 | board outcome Results | Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations ); and in continuation to our letter bearing reference no: WOCK/SEC/SE/2025-26/065AI summaryWockhardt Limited filed the outcome of its board meeting held on 10 February 2026, approving unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025, with a limited review report from statutory auditors M/s MSKC & Associates LLP. Standalone revenue from operations for the quarter ended 31 December 2025 was Rs 430 crore, against Rs 325 crore a year earlier; net profit after tax was Rs 28 crore, against a loss of Rs 22 crore in the year-ago quarter. Standalone revenue from operations for nine months ended 31 December 2025 was Rs 1,223 crore, against Rs 1,047 crore a year earlier; net profit after tax was Rs 150 crore, against a loss of Rs 52 crore. The company recorded Rs 10 crore as an exceptional charge in the quarter for the impact of the new Labour Codes, based on best available information. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 03 Nov 2025 | board outcome Management change, Results | Wockhardt Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.AI summaryBoard of Wockhardt Limited approved the un-audited standalone and consolidated financial results for the quarter and half year ended 30 September 2025, with an auditor's limited review report from MSKC & Associates LLP dated 3 November 2025. The Board appointed Mr. Om Prakash Bhatt (DIN: 00548091) as Additional (Non Executive Independent) Director with effect from 3 November 2025. The Board recommended his appointment as Independent Director for a five-year term till 2 November 2030, subject to shareholder approval by special resolution. The board meeting commenced at 11:45 a.m. and concluded at 2:30 p.m. on 3 November 2025. The filing does not state the revenue or profit figures, as the results annexure was not included in the pages provided. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 26 Aug 2025 | credit rating Rating | Wockhardt Limited has informed the Exchange about Credit RatingAI summaryWockhardt Limited informed BSE and NSE that ICRA Limited has upgraded its credit ratings and revised the outlook from Stable to Positive. Long-term fund-based term loan rated BBB (Positive), previously BBB- (Stable). Long-term/short-term fund-based, non-fund-based and unallocated limits rated BBB (Positive)/A3+, previously BBB- (Stable)/A3. ICRA cited sustained and healthy increase in earnings, cash flow and operating profit margins, improved financial profile, liquidity and debt protection metrics, healthy market position in India, Europe and emerging markets, and launch of new NCE Miqnaf. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 08 Aug 2025 | board outcome Results | Wockhardt Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.AI summaryWockhardt Limited filed the outcome of its board meeting held on 8 August 2025, approving the un-audited standalone and consolidated financial results for the quarter ended 30 June 2025, with a limited review report from statutory auditors M/s. MSKC & Associates LLP. Standalone revenue from operations for the quarter ended 30/06/2025 was Rs 413 crore, against Rs 352 crore in the corresponding quarter of the previous year. Standalone total income was Rs 438 crore, and profit after tax was Rs 69 crore, against Rs 6 crore in the year-ago quarter. Basic and diluted earnings per share were Rs 4.25 (not annualised), against Rs 0.39 in the year-ago quarter. The board meeting commenced at 11:35 a.m. and concluded at 1:45 p.m. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 11 Jun 2025 | transcript Capex, Guidance, Legal, Results | Wockhardt Limited has informed the Exchange about TranscriptAI summaryWockhardt filed the transcript of its investor presentation held on 5 June 2025 (Regulation 30 disclosure), also to be posted on the company website. Dr. Murtaza Khorakiwala (Managing Director) said FY25 turnover was INR 3,033 crore, EBITDA about INR 418 crore, and EBITDA grew 67% with margin expanding from 9% to 14%. Management said ZAYNICH completed a global Phase 3 trial showing 20% superiority to existing treatment, was filed with the DCGI in March 2025, and that US filing is planned in the coming quarter. Management said Miqnaf was approved and launched in India on 27 May 2025, and net debt to equity is now 0.01%, with debt reduced to INR 326 crore after a INR 1,000 crore QIP. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Jun 2025 | presentation Capex, Dividend / buy-back, Legal, Results | Wockhardt Limited has informed the Exchange about Investor PresentationAI summaryWockhardt Limited filed an updated Investor Presentation (June 2025) under Regulation 30, in continuation of its 2 June 2025 letter, and said it will also be posted on the company website. FY25 income was INR 3,033 Cr and FY25 EBITDA was INR 418 Cr, with EBITDA growth as printed on the slide and a net debt to equity ratio of 0.01 (excluding promoter debt, as at 31 March 2025). Reduction in debt of 67% year-on-year (as at 31 March 2025 vs 31 March 2024, excluding promoter debt) was shown; FY25 sales contribution was UK 39%, Emerging Markets 23%, India 23% and Ireland (and other EU) 12%. Management highlighted FY24-25 development milestones, including NDA filing with DCGI for ZAYNICH (WCK 5222), approval and launch of MIQNAF (Nafithromycin) in India, and a INR 1,000 Cr capital raise through QIP. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Jun 2025 | presentation Acquisition, Capex, Dividend / buy-back, Guidance, Legal, Management change, Rating, Results | Wockhardt Limited has informed the Exchange about Investor PresentationAI summaryWockhardt Limited filed its Investor Presentation (June 2025) under Regulation 30, for an investor meeting on 5 June 2025; the deck is also posted on the company website. FY25 income of INR 3,033 Cr and FY25 EBITDA of INR 418 Cr, with EBITDA growth noted year-on-year. Net Debt to Equity ratio of 0.01 as at 31 March 2025; debt reduced by 67% year-on-year (excluding promoter debt). Key FY25 milestones cited include ZAYNICH (WCK 5222) NDA filed with DCGI India, MIQNAF (Nafithromycin) approved and launched in India, and a capital raise of INR 1,000 Cr through QIP. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 02 Jun 2025 | presentation | Wockhardt Limited has informed the Exchange that Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company will hold an Investor meet/call on ThuAI summaryWockhardt Limited intimated under Regulation 30 of the SEBI LODR Regulations, 2015, that it will hold an investor call on Thursday, 5 June 2025 at 11:00 hrs IST, through VC and in-person. The call will begin with a presentation by Dr. Murtaza Khorakiwala, Managing Director, followed by a Q&A session in presence of Dr. Habil Khorakiwala, Chairman. The invite says the call will discuss the Company's performance and future business roadmap. Questions can be sent to investorrelations@wockhardt.com by 4 June 2025; in-person registration closes at 2:00 PM IST on 4 June 2025. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 May 2025 | board outcome Capex, Management change, Results | Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations ); please find enclosed herewith outcome of the board meeting held today i.e. May AI summaryBoard meeting outcome filed on 29 May 2025 by Wockhardt Limited (WOCKPHARMA), which approved the audited standalone and consolidated financial results for the quarter and year ended 31 March 2025, with the statutory auditor's report (M/s. MSKC & Associates) enclosed. The Board re-appointed Mr. Akhilesh Krishna Gupta as Independent Director for a second five-year term from 29 August 2025 to 28 August 2030, subject to shareholder approval at the ensuing AGM. The Board appointed Mr. Virendra G. Bhatt, Practicing Company Secretary, as Secretarial Auditor for five consecutive years up to the Thirty First AGM, subject to shareholder approval. The Board approved an enabling proposal to raise funds through equity, convertible or non-convertible securities in one or more tranches, subject to shareholder approval at the AGM. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Feb 2025 | results Results | Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31st December, 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated 2nd January, 2025, we are submitting herewith the Integrated FiliAI summaryWockhardt Limited filed its integrated financial filing for the quarter and nine months ended 31 December 2024, including standalone unaudited results reviewed by MSKC & Associates LLP. Standalone revenue from operations for Q3 FY25 (3 months ended 31/12/2024) was Rs 325 crore, against Rs 370 crore in the previous quarter and Rs 288 crore in the year-ago quarter. Standalone net loss after tax for the quarter was Rs 22 crore, against a net loss of Rs 36 crore in the previous quarter and Rs 74 crore in the year-ago quarter. For nine months ended 31/12/2024, standalone revenue from operations was Rs 1,047 crore and net loss after tax was Rs 52 crore, against Rs 799 crore revenue and Rs 296 crore loss a year earlier. Basic loss per share (face value Rs 5) for the quarter was Rs 1.40, not annualised. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Feb 2025 | results Results | Wockhardt Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.AI summaryWockhardt Limited filed the outcome of its board meeting held on 7 February 2025, approving unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2024, with a limited review report from statutory auditors M/s. MSKC & Associates LLP. Standalone revenue from operations was Rs 325 million for the quarter ended 31 December 2024 (Rs 370 million in the previous quarter; Rs 288 million a year earlier) and Rs 1,047 million for nine months (Rs 799 million a year earlier). Standalone net loss after tax was Rs 22 million for the quarter ended 31 December 2024, against Rs 74 million a year earlier, and Rs 52 million for nine months, against Rs 296 million a year earlier. Basic loss per share (not annualised) was Rs 1.40 for the quarter and Rs 3.36 for nine months. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.